ArticleMaterials today. Bio2025
Rapamycin-induced small extracellular vesicles under GelMA scaffolds facilitate diabetic wound repair through accelerating angiogenesis and alleviating macrophage-mediated inflammation via PI3K/Akt signaling pathway.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- ABHD17C-Mediated S-Depalmitoylation of BCL6B Enhances CD24 Transcription to Resist Macrophage Phagocytosis in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Procyanidin capsules attenuate PI3K/AKT-mediated mitochondrial dysfunction and accelerate skin wound healing in diabetic mice.Materials today. Bio · 2026Article
- β‑Ecdysone-Loaded Gelatin Methacryloyl Hydrogel Accelerates Diabetic Wound Healing by Improving Angiogenesis.ACS omega · 2026Article
- [Research advances on the targeted programmed cell death regulatory network for treatment of refractory diabetic wounds].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Review
- Photothermal-responsive MXene/curcumin-copper composite hydrogel with antioxidant, immunoregulatory, and angiogenic functions for diabetic wound healing.Journal of nanobiotechnology · 2026Article
- De Novo Design Strategies of Nanomedicines for Diabetic Wound Microenvironment Remodeling.BME frontiers · 2026Review
- Small Extracellular Vesicles in Neurodegenerative Disease: Emerging Roles in Pathogenesis, Biomarker Discovery, and Therapy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, small extracellular vesicles (sEVs) isolated from mesenchymal stem cells (MSCs) show superior therapeutic potential in diabetic wound repair. Pretreated MSCs with biological or chemical agents could boost the activities of MSC-derived sEVs. This study aims to investigate whether sEVs derived from the human umbilical cord MSCs (hUCMSCs) pretreated with rapamycin (RAPA) exhibit elevated efficacy in improving diabetic wound healing and to elucidate the underlying mechanisms involved. The sEVs extracted from RAPA pretreated hUCMSCs (RAPA-sEVs) were successfully characterized in terms of their morphology, structural features, and concentration. In vitro studies revealed that RAPA-sEVs suppressed the proliferative and migratory capabilities of macrophages and reduced the expression of pro-inflammatory mediators including TNF-α, IL-1β and iNOS. Meanwhile, they promoted the migration and tube formation of endothelial cells, and increased the level of VEGF. More importantly, full-thickness skin defect models were established in streptozotocin (STZ)-induced diabetic mice. Gelatin methacryloyl (GelMA) carrying sEVs applied to the surface of damaged skin. RAPA-sEVs exhibited exceptional efficacy in accelerating the wound repair via propelling angiogenesis, reducing the percentage of M1-type macrophages, and mitigating excessive inflammatory response under superior biosafety conditions. Mechanistically, the biological activities of RAPA-sEVs were dependent on the PI3K/Akt signaling pathway, and the pro-angiogenic and anti-inflammatory effects of RAPA-sEVs were alleviated after the pathway being inhibited by a PI3K inhibitor PI103. Overall, RAPA-sEVs-based therapy might serve as a promising strategy for diabetic wound healing through fueling angiogenesis and alleviating macrophage-mediated inflammation via activating PI3K/Akt signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.